Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma

Neuro-Oncology

Volumn 17, Issue 8, 2015, Pages 1043-1045

  Vlahovic, Gordana ^a   Fecci, Peter E ^a   Reardon, David ^b   Sampson, John H ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; AMP 514; ANTINEOPLASTIC AGENT; AVELUMAB; BMS 936559; DURVALUMAB; IPILIMUMAB; MEDI 0680; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; BLADDER CANCER; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG TARGETING; EDITORIAL; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOMA; MELANOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; TIGHT JUNCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; BRAIN TUMOR; METABOLISM;

ANTIGENS, CD274; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84941022540     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov071     Document Type: Editorial

References (17)

1. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107-116.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
3. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
4. Yervoy [package insert]. Princeton NJ, Bristol-Myers Squibb 2013.
5. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co., 2015.
6. Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2014.
7. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587.
8. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-88.
9. Bloch O, Crane CA, Kaur R, et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165-3175.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
11. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-5074.
12. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
13. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol. 2013;31(34):4311-4318.
14. Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today. 1992;13(12):507-512.
15. Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48-65.
16. Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014; 6(247):p247ra101.
17. Zalutsky MR, Moseley RP, Coakham HB, et al. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989;49(10): 2807-2813.